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Gestational diabetes (GDM) complicates up to 10% of pregnancies. In addition to acute risks, the children 
of diabetic mothers have an increased risk of obesity, diabetes, and hypertension, starting in childhood. 
While the causes of this increased risk are unknown, previous studies in our lab have identified functional 
deficits in endothelial colony forming cells (ECFCs) isolated from the cord blood of GDM pregnancies. 
This study focused on identifying genes that have altered epigenetic modifications that result in abnormal 
mRNA and protein expression in ECFCs from the cord blood GDM pregnancies. The objective of this 
study was to identify mRNA expression and DNA methylation alterations in ECFCs that may help 
identify the causes of ECFC dysfunction following intrauterine exposure to GDM. ECFCs were obtained 
from control and GDM pregnancies. DNA, RNA, and protein samples were isolated in parallel from 
ECFCs. RNA microarray analysis using the Affymetrix Human 1.0 Gene Array was used to identify gene 
expression alterations in GDM ECFCs compared to control ECFCs. Genome-wide DNA methylation was 
assessed using an Infinium 450K Methylation Array for DNA samples at >450,000 CpG sites. Correlation 
analysis was performed to identify possible sites that have altered CpG methylation and RNA expression. 
RNA expression results were validated using qRT-PCR and western blotting. Bisulfite sequencing of 
genomic DNA from the ECFCs was performed to identify additional sites with altered methylation for 
regions not included in the DNA methylation array. Of the 28,000 genetic loci tested, 596 mRNAs were 
altered between control and GDM ECFCs (p<0.01). More stringent criteria identified 38 genes for further 
investigation by limiting analysis to genes that exhibited increased or decreased expression by at least 
50%, with a p<0.01. PLAC8 was identified as being increased 5-fold by microarray analysis, a result 
which was confirmed in two cohorts by qRT-PCR and western blotting. Analysis of the methylation array 
and bisulfite sequencing results revealed 3 regions surrounding the transcriptional start site of PLAC8 
gene whose CpG methylation negatively correlate with RNA expression in samples from control and 
GDM ECFCs. In contrast, a CpG island is fully unmethylated in both control and GDM ECFCs. The 
discovery of CpG sites whose methylation correlates with PLAC8 mRNA expression in ECFCs is 
consistent with the hypothesis that intrauterine exposure to GDM results in epigenetic changes. Analysis 
of methylation at this site could be used as a biomarker for children of mothers with GDM who may be at 
risk for disease later in life. Using bisulfite pyrosequencing, we are currently developing assays to quickly 
determine if methylation of the PLAC8 putative promoter region is altered in cord blood mononuclear 
cells obtained from GDM or healthy control pregnancies. We are also investigating the role of 
methylation in regulating PLAC8 RNA expression, determining if there is altered histone modifications 
and transcription factor binding in these regions, and examining other genes that may comprise a 
molecular signature of ECFC dysfunction. 
